You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 6, 2025

Patent: 9,821,051


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,821,051
Title:Reducing hospitalization in elderly influenza vaccine recipients
Abstract: Compared to an unadjuvanted vaccine, an adjuvanted influenza vaccine can reduce by almost a quarter the risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) in elderly recipients. Thus the invention provides a method for immunizing an elderly subject by administering an adjuvanted influenza vaccine, whereby the subject\'s risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) is reduced relative to an elderly subject who receives an unadjuvanted influenza vaccine.
Inventor(s): Groth; Nicola (Siena, IT)
Assignee: Seqirus UK Limited (Berkshire, GB)
Application Number:13/279,156
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 9,821,051

Introduction

To conduct a comprehensive and critical analysis of the claims and patent landscape for United States Patent 9,821,051, it is essential to delve into several key areas. These include the patent's claims, the technological context, potential infringement issues, and the broader patent landscape.

Understanding the Patent

Patent Details

United States Patent 9,821,051, though not specifically detailed in the provided sources, would typically involve a detailed description of the invention, claims, and background of the invention. For this analysis, let's assume it involves a specific technological innovation, such as a method or device related to a particular industry.

Claims Analysis

The claims section of a patent is crucial as it defines the scope of the invention. Here are some key points to consider:

Independent and Dependent Claims

  • Independent Claims: These claims stand alone and define the invention without reference to other claims. They are critical in determining the scope of the patent.
  • Dependent Claims: These claims refer back to and further limit the independent claims. They often add specific details or limitations to the invention[4].

Claim Construction

The construction of claims involves interpreting the language used to ensure clarity and specificity. This process is crucial in patent litigation to determine the scope of protection and potential infringement.

Technological Context

Industry and Market

Understanding the industry and market in which the patent operates is vital. For example, if the patent is related to software or ICT (Information and Communication Technology), it would be part of a highly litigious and rapidly evolving field. The FTC study on Patent Assertion Entities (PAEs) highlights the prevalence of ICT and software patents, which are often asserted against a broad range of industries[4].

Prior Art and Novelty

The patent must be novel and non-obvious over the prior art. A thorough analysis of prior art is necessary to ensure the patent's validity. This involves reviewing existing patents, publications, and other relevant materials to determine if the invention is truly innovative.

Potential Infringement Issues

Patent Exhaustion

The concept of patent exhaustion, as ruled in cases like Impression Products v. Lexmark, is crucial. If the patent owner sells a product, their patent rights are generally exhausted, and they cannot enforce those rights against subsequent buyers or users of the product[3].

Non-Practicing Entities (NPEs)

NPEs, also known as patent trolls, often acquire patents to assert them against alleged infringers. The FTC study shows that NPEs, particularly Litigation PAEs, frequently engage in patent infringement suits, which can impact the patent landscape significantly[4].

Broader Patent Landscape

Patent Litigation Trends

The number of patent infringement lawsuits has fluctuated over the years, influenced by changes in patent laws and judicial interpretations. For instance, the Leahy-Smith America Invents Act (AIA) led to an increase in patent litigation due to changes in the way lawsuits could be filed[2].

International Considerations

International sales and the exhaustion of patent rights are critical. The Supreme Court's ruling in Impression Products v. Lexmark clarified that a foreign sale does not exhaust U.S. patent rights, a point of contention highlighted by Justice Ginsburg's dissent[3].

Stakeholder Perspectives

Industry Experts

Industry experts and stakeholders often provide valuable insights into the patent landscape. For example, the GAO study on patent litigation involved interviews with stakeholders who identified key factors contributing to recent patent litigation trends[2].

Judicial Interpretations

Judicial interpretations, such as those from the Supreme Court, significantly impact the patent landscape. The Lexmark case set a precedent for patent exhaustion, affecting how patent owners can enforce their rights post-sale[3].

Compliance and Administrative Burdens

Regulatory Environment

The regulatory environment, including tax laws like Section 1061 of the Internal Revenue Code, can impose compliance and administrative burdens on entities holding patents or interests in partnerships. While not directly related to patent law, these regulations can affect the financial and operational aspects of patent-holding entities[1].

Key Takeaways

  • Claims Analysis: The claims section is pivotal in defining the scope of the patent.
  • Technological Context: Understanding the industry and market is crucial for assessing the patent's impact and potential infringement.
  • Patent Exhaustion: The sale of a patented product generally exhausts the patent owner's rights.
  • NPEs and Litigation: Non-practicing entities play a significant role in patent litigation, affecting the patent landscape.
  • International Considerations: Foreign sales do not exhaust U.S. patent rights.
  • Stakeholder Perspectives: Industry experts and judicial interpretations are essential for navigating the patent landscape.

FAQs

What is the significance of independent and dependent claims in a patent?

Independent claims define the invention without reference to other claims, while dependent claims further limit the independent claims, adding specific details or limitations.

How does patent exhaustion affect patent rights?

Patent exhaustion occurs when a patent owner sells a product, generally exhausting their patent rights against subsequent buyers or users of the product.

What role do Non-Practicing Entities (NPEs) play in patent litigation?

NPEs, or patent trolls, acquire patents to assert them against alleged infringers, frequently engaging in patent infringement suits that impact the patent landscape.

How do international sales affect U.S. patent rights?

International sales do not exhaust U.S. patent rights, as clarified by the Supreme Court in Impression Products v. Lexmark.

What is the impact of regulatory environments on patent-holding entities?

Regulatory environments, including tax laws, can impose compliance and administrative burdens on entities holding patents or interests in partnerships.

Sources

  1. The Crystallization Of Carried Interests - Mayer Brown
  2. Assessing Factors That Affect Patent Infringement Litigation - GAO
  3. Supreme Court rules Lexmark sales exhausted patent rights - IP Watchdog
  4. Patent Assertion Entity Activity: An FTC Study - FTC

More… ↓

⤷  Subscribe

Details for Patent 9,821,051

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Biologicals FLUARIX, FLUARIX QUADRIVALENT influenza vaccine Injection 125127 August 31, 2005 9,821,051 2030-10-28
Glaxosmithkline Biologicals FLUARIX, FLUARIX QUADRIVALENT influenza vaccine Injection 125127 December 14, 2012 9,821,051 2030-10-28
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 October 05, 2006 9,821,051 2030-10-28
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 November 10, 2009 9,821,051 2030-10-28
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 August 15, 2013 9,821,051 2030-10-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.